Identification of actionable biomarkers continues to drive application of precision medicine in oncology. For patients with lung cancer, molecularly targeted therapies based on expression of specific biomarkers may be potential treatment options. Only through biomarker testing can clinicians discover whether lung cancers have targetable biomarkers.
Despite increasing evidence supporting the role of biomarkers in treatment decision-making for patients with lung cancer, recent studies1-3 report that more than 70 percent of patients treated in the community do not receive biomarker testing as recommended by National Comprehensive Cancer Network (NCCN) clinical practice guidelines, and more than 50 percent of patients do not receive appropriate precision medicine therapies based on the test results.2 Among underserved patient populations, the gap is even wider.4,5 Analysis of CMS claims data has revealed that Medicaid patients are 40 percent less likely to get tested than patients with private health insurance and Medicaid patients are 30 percent less likely to receive targeted therapies after testing, compared to patients with private health insurance.4
The ACCC Eliminating Precision Medicine Disparities project is focused on understanding specific barriers and challenges to equal access to precision medicine among underserved patient communities. Through this project, ACCC seeks to:
The project is guided by an expert multidisciplinary Advisory Committee. ACCC is pleased to partner with LUNGevity for the patient-facing components of this education intervention.
If you are interested in learning more about this project, please contact Janelle Schrag, Assistant Director of Research Programs, ACCC Provider Education.
Survey Examines Oncology Clinician Perceptions of Biomarker Testing for Underserved Patients With Lung Cancer
Sep 15, 2021
Lung Cancer Biomarker Testing Survey Reveals Access Gaps, Attitudes in Community, Academic Practices
Sep 15, 2021
Minority of Clinicians Understand, Use Biomarker Guidelines in NSCLC Treatment or Patient Discussions
Sep 14, 2021
Association of Community Cancer Centers Releases Report at IASLC 2021
Sep 13, 2021
Biomarker testing decisions for lung cancer vary between academic, community oncologists
Sep 11, 2021
Funding & support provided by Genentech, Janssen, Merck & Co., and Foundation Medicine